REDWOOD CITY, Calif. — August 14, 2025 — Leads & Copy — Bolt Biotherapeutics (Nasdaq: BOLT) reported its second-quarter financial results, highlighting the advancement of BDC-4182, a next-generation Boltbody™ ISAC, now in Phase 1 for gastric and gastroesophageal cancer patients in Australia. The company anticipates presenting initial data in the first half of 2026 and is seeking a partner for BDC-3042, a dectin-2 agonist antibody that showed activity in lung cancer patients.
Bolt’s BDC-4182 Phase 1 study is enrolling patients with gastric and gastroesophageal cancer. BDC-4182 targets claudin 18.2, which is expressed in several tumor types. Preclinical data showed complete regressions in multiple models, with BDC-4182 outperforming cytotoxic claudin 18.2 ADCs.
Collaborations with Genmab and Toray continue to progress, advancing multiple development candidates. Bolt is seeking a partner for further development of BDC-3042, following a KOL conference call discussing Phase 1 study results presented at the AACR Annual Meeting in April 2025.
The company’s cash, cash equivalents, and marketable securities totaled $48.5 million as of June 30, 2025, expected to fund operations through mid-2026.
Second Quarter 2025 Financial Results:
- Collaboration Revenue: $1.8 million, up from $1.3 million in 2024.
- R&D Expenses: $7.5 million, down from $15.4 million in 2024 due to decreased salary and clinical expenses.
- G&A Expenses: $3.5 million, down from $4.9 million in 2024 due to restructuring.
- Loss from Operations: $9.2 million, compared to $22.6 million in 2024.
Other Developments: A one-for-twenty reverse stock split was effected on June 6, 2025, leading to compliance with Nasdaq’s minimum bid price requirement.
Matthew DeYoung, Argot Partners, (212) 600-1902, boltbio@argotpartners.com
Source: Bolt Biotherapeutics
